Brief: Elicio Therapeutics Announces Preliminary Disease-Free Survival Analysis From The Ongoing Amplify-7P Phase 1A Study Of Eli-002 7P
27/06/2024 21:33
Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS ANNOUNCES PRELIMINARY DISEASE-FREE
SURVIVAL
ANALYSIS FROM THE ONGOING AMPLIFY-7P PHASE 1A STUDY OF ELI-002
7P
* ELICIO THERAPEUTICS INC - PROVIDING ADDITIONAL CLINICAL
DATA
UPDATES FROM AMPLIFY PHASE 1 TRIALS EXPECTED LATER IN 2024
Source text for Eikon: ID:nGNXbHCJpb
Further company coverage: ELTX.O
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)